Anthera Pharmaceuticals (ANTH) Stock: Climbing On Clinical Update

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on ANTH. In particular, we’re interested in following the ongoing news surrounding RESULT and excited to see the full top line results. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required

Leave a Comment